PTPN2 and neoplasm: Although neither PTP1B nor PTPN2 deletion affected NK development or tumor growth in vivo, and the inhibitor did not affect NK cell activation in vitro, it is likely that the increased abundance of NK cells and consequent increased IFNγ production contribute to the therapeutic efficacy of Compound 182 in vivo.